<DOC>
	<DOCNO>NCT02744742</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) appear efficient tool cure refractory anemia excess blasts-1 ( RAEB-1 ) , refractory anemia excess blasts-2 ( RAEB-2 ) acute myeloid leukemia ( AML ) secondary myelodysplastic syndrome ( MDS ) . At present , best condition regimen RAEB-1 , RAEB-2 AML secondary MDS undergo allo-HSCT remains discussion . In study , safety efficacy Decitabine + BUCY BUCY myeloablative conditioning regimens patient RAEB-1 , REAB-2 AML Secondary MDS undergo allo-HSCT evaluate .</brief_summary>
	<brief_title>Decitabine+BUCY v BUCY Conditioning Regimen RAEB-1 , REAB-2 AML Secondary MDS Undergoing Allo-HSCT</brief_title>
	<detailed_description>Allo-HSCT appear efficient tool cure patient MDS AML secondary MDS . At present , best condition regimen MDS AML secondary MDS undergo allo-HSCT remains discussion . BUCY condition regimen standard myeloablative regimen MDS AML secondary MDS undergo allo-HSCT . However , appear high relapse rate . To reduce relapse rate , decitabine add condition regimen . In study , safety efficacy Decitabine + BUCY BUCY myeloablative conditioning regimens RAEB-1 , REAB-2 AML secondary MDS undergo allo-HSCT evaluate .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>RAEB1 , REAB2 AML Secondary MDS undergo alloHSCT 1465 year Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>